Capivasertib is an AKT inhibitor used to treat hormone receptor–positive/HER2-negative locally advanced or metastatic breast cancer that has one or more mutations in the PIK3CA, AKT1, or PTEN tumor genes. It is given in pill form in combination with fulvestrant (Faslodex®).
Support research with a legacy gift. Sample, non-binding bequest language:
I give to the Breast Cancer Research Foundation, located in New York, NY, federal tax identification number 13-3727250, ________% of my total estate (or $_____).
Stay in the know with the latest research news, insights, and resources delivered to your inbox.
Follow BCRF on all the major platforms for research news, inspiring stories, and more.
